By: Matt Emma
Philosophy, science, and curiosity have always intertwined in Brandon Emerick’s view of the world. “People say philosophy isn’t a practical subject, but in my experience, it most certainly is,” he says. “It underlies everything.” That belief has guided his journey from cognitive science to business administration and, eventually, to founding BlissGene Therapeutics in 2024, a venture exploring how genetics and technology might help reimagine humanity’s relationship with pain and emotion.
Emerick’s fascination with the mind began at the age of twelve, drawn to philosophical questions about consciousness and well-being. That curiosity evolved into a passion for cognitive science, which he studied at a University in Connecticut. “I believe cognitive science can link neuroscience, AI, anthropology, psychology, linguistics, and philosophy into one field,” he explains. “It’s one thing to study brain activity, another to study emotion, behavior, cognition, and another to link it all together into how a mind fundamentally works.”
His academic path shifted when he realized the competitive realities of a university career. Switching to business administration allowed him to pair practical skills with his scientific interests, a combination that would later shape his entrepreneurial work. It was during this period that he came across reports of a woman with a rare genetic mutation that left her largely immune to pain, anxiety, and fear. The discovery revealed a mutation of a new gene named FAAH-OUT, which mediated the expression of the FAAH gene, part of the endocannabinoid system, responsible for pain, mood, and memory.
Emerick began to wonder whether this biological anomaly could hold insights into how humans experience discomfort and distress. “It led me to believe that pain might not be as essential as we think,” he says. “Perhaps we don’t need to experience it in the same intensity we do now.” That realization became the starting point for BlissGene Therapeutics, where his focus lies in exploring gene-based methods that could potentially reduce chronic pain and emotional suffering.
The company’s research framework involves a gene-editing technology that could allow for precise DNA modifications and may mimic the effect of the mutation on other genes. The aim, Emerick explains, is not to erase pain but to lessen its overwhelming impact by regulating the body’s natural pain responses. “You’d still need to recognize an injury or illness,” he says, “but maybe you wouldn’t have to endure it as sharply.”
BlissGene Therapeutics is still in the early stages, with a small team collaborating internationally while awaiting funding. Among them, Emerick notes, are members who have been in the fields of cancer research, bioengineering, and lipid nanoparticles, an innovation that could help deliver gene therapies directly through the blood-brain barrier. Emerick estimates that it may take up to ten years for the therapy to move from research to real-world testing. “The science is sound, but like most breakthroughs, it needs time and support,” he notes.
While that project develops, Emerick is already introducing a more immediate innovation: the Mood Amplifier, an app designed to elevate emotional states through AI and neurofeedback. Paired with a simple EEG headband, the system interprets brainwave data and gently guides users toward more balanced or uplifted moods. “If it can read your emotional state, it might also help improve it,” he says. The app, he adds, reflects his broader mission to make emotional well-being more accessible through everyday technology.
Emerick’s work grows from a conviction that humanity’s understanding of suffering can evolve alongside science. He believes that modern approaches to health and happiness could integrate philosophy, technology, and genetics in ways that encourage resilience rather than dependence. “We need to use what we know to help people feel more at ease in their own minds,” he says. He has also shared his scientific insights with an audience at a TEDx Talk conference, inspiring many to understand the psychology behind curiosity.
That vision, rooted in science and philosophy, continues to shape BlissGene Therapeutics as it moves forward. Emerick views the work as an exploration of what defines human experience. “We’re asking how biology and consciousness interact,” he says. “And if we can learn from that connection, maybe one day we can better understand what it truly means to feel at peace.”
Disclaimer: The information provided in this article reflects the views and insights of Brandon Emerick and his work with BlissGene Therapeutics. The research and technologies discussed are in the early stages of development and have not yet been proven or tested in real-world settings. The content is for informational purposes only and should not be construed as medical, therapeutic, or scientific advice. Readers are encouraged to seek professional advice before making decisions related to health or well-being.
